Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A number of common eye diseases such as age-related macular degeneration and glaucoma are associated with ocular perfusion abnormalities. Although this is well recognized there is not much possibility to improve blood flow to the posterior pole of the eye in these diseases.
For many years, moxaverine has been used in the therapy of perfusion abnormalities in the brain, the heart and the extremities. This is based on a direct vasodilatatory effect of the drug, but also on the rheological properties of red blood cells. In a recent study the investigators have shown that intravenous moxaverine increases choroidal blood flow in healthy young subjects. The present study aims to investigate, whether moxaverine also improves blood flow in the diseased eye after systemic administration.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | 20 patients with age related macular degeneration |
|
| 2 | Experimental | 20 patients with primary open angle glaucoma |
|
| 3 | Experimental | 20 age and sex matched control subjects |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| moxaverine | Drug | intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Choroidal and optic nerve head blood flow | 2 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Retrobulbar flow velocities | 2 hours | |
| Retinal blood flow velocity | 2 hours | |
| Retinal venous and arterial diameters |
Not provided
Inclusion Criteria:
AMD patients:
Glaucoma patients:
Healthy control subjects:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Clinical Pharmacology, Medical University of Vienna | Vienna | 1090 | Austria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| moxaverine | Drug | intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes. |
|
|
| moxaverine | Drug | intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes. |
|
|
| 2 hours |
| Intraocular pressure | 2 hours |
| Systolic and diastolic blood pressure | 2 hours |
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| D005901 | Glaucoma |
| ID | Term |
|---|---|
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D009798 | Ocular Hypertension |
Not provided
Not provided
| ID | Term |
|---|---|
| C004490 | moxaverine |
Not provided
Not provided
Not provided